Clinical Trials Logo

Filter by:
NCT ID: NCT05936138 Completed - Healthy Clinical Trials

A Study of LY3502970 in Participants With Normal and Impaired Renal Function

Start date: July 13, 2023
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3502970 will also be evaluated in these participants. The study will last up to 6 weeks including screening period.

NCT ID: NCT05935917 Completed - Smallpox Clinical Trials

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

BCV-001
Start date: May 30, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate whether both Form H and Form II, 100mg brincidofovir tablets are bioequivalent, when given under fasting conditions in healthy adults. Participants will be randomized to each receive one tablet of Form H and one tablet of Form II,14 days apart and undergo pharmacokinetic testing pre-dose and post-dose to evaluate safety. This is an open-label, single-dose, randomized, two-period, crossover study.

NCT ID: NCT05935631 Completed - Neural Tube Defects Clinical Trials

Feasibility, Acceptability and Directional Signal Effect on Blood Folate Levels of Iodized Salt Fortified With Folic Acid: Clinical Study

FASALT
Start date: January 24, 2023
Phase: N/A
Study type: Interventional

Aim 1: Assess directional signal of effect of fortified salt with folic acid and iodine on blood serum folate levels. It will be accomplished by feasibility pre-test/post-test clinical study by estimating mean and variability of serum blood folate levels effects of folic acid fortified salt. Hypothesis: Fortified salt with folic acid and iodine will increase serum blood folate levels from baseline by month 1. Aim 2: Assess feasibility and acceptability of salt fortified with folic acid and iodine. Feasibility will be measured by 1) subjects' refusal rate of consent by 30 subjects during 6-month enrollment period; 2) method of determining salt consumption (weighting the saltshaker pre and post); 3) completion rates of study protocols from baseline to follow up. Hypothesis 1a: Completion of all blood draw visits will be 90-100%. Acceptability will be measured by 1) completion rate of daily salt logs; 2) consumption of salt by weighting saltshakers; 3) attitude towards taste and color difference. Hypothesis 1b: Completion rate (90-100%) of daily salt logs will range from 90-100% of participants and 2) consumption of salt will range from 90-100% of participants. Dietary surveys will be employed to document dietary habits and estimated daily FA intake in the sample population. Feasibility and acceptability of dietary surveys will be measured by willingness to answer survey questions. Hypothesis 1c: Completion rate of dietary surveys will range 90-100%.

NCT ID: NCT05934604 Completed - Clinical trials for Healthy Participants

Targeting Large-scale Networks in Depression With Real-time fMRI (Functional Magnetic Resonance Imaging) Neurofeedback

Start date: October 9, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to develop a technique called real time fMRI neurofeedback. This technique uses a functional MRI scanner, except that special software allows the researchers to measure activity in participants brain, using fMRI, and then give information, in the form of a feedback signal, which indicates brain activity in real time, while in the MRI scanner. The larger goal of this study is to develop ways to help people, including those with depression, better regulate brain activity. The researchers think that this may be helpful in managing psychiatric symptoms. This study design has three phases, however, only two phases (phase 2 and 3) are considered to be a clinical trial. Therefore, this registration will include phase 2 at this time.

NCT ID: NCT05934292 Completed - Clinical trials for Hypercholesterolaemia

MK-0616 (Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020)

Start date: July 20, 2023
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to compare the plasma pharmacokinetics (PK) of MK-0616 following a single 20 mg dose in participants on a background of statin therapy with varying degrees of renal impairment (moderate, severe, end stage renal disease [ESRD]) to those of healthy mean matched control participants on a background of statin therapy. There is no formal hypothesis.

NCT ID: NCT05933772 Completed - Astigmatism Clinical Trials

Performance Evaluation of Two Silicone Hydrogel Toric Lens Designs in Habitual Soft Contact Lens Wearers

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

The objective of the study is to compare the clinical performance of two monthly toric silicone hydrogel contact lenses in habitual wearers, when worn for 1-month each.

NCT ID: NCT05933746 Completed - Sleep Disturbance Clinical Trials

Sleep Hygiene Intervention on Undergraduate Students' Sleep and Stress

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Poor sleep is common among college students and likely contributes to stress. The investigators developed a brief, remotely-delivered intervention and tested whether it improves sleep hygiene and reduced sleep disturbance and stress among undergraduates.

NCT ID: NCT05933447 Completed - Healthy Clinical Trials

Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart

Start date: May 12, 2023
Phase: Phase 1
Study type: Interventional

To evaluate whether Rodatristat Ethyl prolongs the QTc interval when orally administered to healthy volunteers.

NCT ID: NCT05933187 Completed - Clinical trials for Healthy Participants

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

Start date: July 19, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to evaluate plasma concentrations of emraclidine following single dose oral administration of different emraclidine immediate release (IR) tablets in healthy participants.

NCT ID: NCT05932901 Completed - Clinical trials for Chronic Kidney Disease

OPTIMISE-CKD Drug Utilization

OPTIMISE-CKD
Start date: May 4, 2022
Phase:
Study type: Observational

This is a multi-national, observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in CKD and potential for further utilisation, 2), the current CKD treatment landscape and 3) real-world effectiveness of dapagliflozin in CKD (pending feasibility assessment).